Source:http://linkedlifedata.com/resource/pubmed/id/16793908
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
2006-9-28
|
| pubmed:abstractText |
Many previous reports have demonstrated that systemic administration of endostatin (ES), a proteolytic cleavage product of collagen type XVIII and an endogenous angiogenesis inhibitor, represses tumor angiogenesis in different preclinical tumor models with varying efficacy. For example, systemic delivery of recombinant ES to rat insulin promoter 1 (Rip1)T-antigen 2 (Tag2)-transgenic mice, a mouse model of pancreatic beta-cell carcinogenesis, has repressed tumor angiogenesis efficiently and with it, tumor growth. Here, we report that the transgenic expression of ES in Rip1ES-transgenic mice only interferes moderately with tumor growth in Rip1Tag2;Rip1ES double-transgenic mice. Tumor incidence is not reduced by the local expression of ES, and tumor outgrowth and progression to tumor malignancy are only retarded slightly. A significant effect of local ES expression on tumor angiogenesis is only apparent during the early stages of tumor development, where less angiogenic hyperplastic lesions are observed. Although efficiently produced and secreted by transgenic beta cells, locally expressed ES appears to be sequestered in the microenvironment, and its systemic levels are not increased. The results indicate that the antiangiogenic functions of ES critically depend on the mode of delivery and the site of expression: although its systemic application represses tumor angiogenesis and tumor growth efficiently, locally expressed ES appears to be less effective, and hence, additional mechanisms of solubilization or activation of latent ES seem to be required. These results have important implications about the modes of delivery used in antiangiogenic, therapeutic strategies, which are based on the antiangiogenic activities of ES.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Oct
|
| pubmed:issn |
0741-5400
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
80
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
669-76
|
| pubmed:dateRevised |
2011-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:16793908-Angiogenesis Inhibitors,
pubmed-meshheading:16793908-Animals,
pubmed-meshheading:16793908-Antigens, Polyomavirus Transforming,
pubmed-meshheading:16793908-Carcinoma, Islet Cell,
pubmed-meshheading:16793908-Cell Proliferation,
pubmed-meshheading:16793908-Crosses, Genetic,
pubmed-meshheading:16793908-Disease Models, Animal,
pubmed-meshheading:16793908-Disease Progression,
pubmed-meshheading:16793908-Endostatins,
pubmed-meshheading:16793908-Female,
pubmed-meshheading:16793908-Humans,
pubmed-meshheading:16793908-Insulin,
pubmed-meshheading:16793908-Male,
pubmed-meshheading:16793908-Mice,
pubmed-meshheading:16793908-Mice, Inbred C57BL,
pubmed-meshheading:16793908-Mice, Transgenic,
pubmed-meshheading:16793908-Neoplasms, Experimental,
pubmed-meshheading:16793908-Neovascularization, Pathologic,
pubmed-meshheading:16793908-Pancreas,
pubmed-meshheading:16793908-Pancreatic Neoplasms,
pubmed-meshheading:16793908-Rats,
pubmed-meshheading:16793908-Transgenes
|
| pubmed:year |
2006
|
| pubmed:articleTitle |
Moderate antiangiogenic activity by local, transgenic expression of endostatin in Rip1Tag2 transgenic mice.
|
| pubmed:affiliation |
Department of Clinical-Biological Sciences, University of Basel, Mattenstrasse 28, CH-4058 Basel, Switzerland.
|
| pubmed:publicationType |
Journal Article
|